Syneos Health

What Syneos Health does

Syneos Health is a fully integrated biopharmaceutical solutions organization delivering clinical development and commercialization services to biotech (approximately 70% of portfolio) and top-20 global pharmaceutical customers across more than 40 countries. The company operates a dual model: full-service clinical and commercial delivery, and FSP 360, a Functional Service Provider model where Syneos embeds specialized cross-functional teams within sponsor organizations while sponsors retain strategic control.

The technology platform centers on a portfolio of proprietary and partner-integrated products: PatientGO (patient concierge mobile app with AI at trial delivery points), Kinetic (commercial intelligence with real-time field data and AI-powered engagement), Mindset Engine (behavioral intelligence on ~14,000 HCPs), Synopsis (clinical study oversight and predictive risk detection), PV Hub and PVCI (Azure-based pharmacovigilance with Gen AI case intake), AI MSL Solutions, and MODAL learning platform, with Veeva-preferred services for Veeva Vault CDMS and Microsoft Azure OpenAI Service as core infrastructure.

Syneos generates revenue through professional services engagements — fee-for-service clinical trials, FSP managed services, commercialization deployment (field sales teams, medical science liaisons, engagement centers), medical affairs, real-world evidence, and consulting — priced via bespoke B2B quotes rather than public pricing. The customer base spans enterprise pharma (multi-year anchor contracts exceeding 10 years with top-20 pharma) and a long tail of stealth, emerging, and established biotechs. Operations span North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa, with a 26,000+ workforce including 480+ MDs, 750+ PhDs, and 1,700+ safety/pharmacovigilance staff. The company was taken private in 2023 via a $7.1 billion buyout by Elliott Investment Management, Patient Square Capital, and Veritas Capital, and is no longer publicly traded.

Name

Syneos Health

Legal name

Syneos Health, Inc.

Website

https://syneoshealth.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Syneos Health is a fully integrated biopharmaceutical solutions organization delivering clinical development and commercialization services to biotech (~70% of portfolio) and top-20 global pharma customers across 40+ countries, operating both full-service and FSP 360 engagement models.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) and Biopharmaceutical Commercialization Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Management Consulting Services (54161)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Management Consulting Services (8742), Services-Health Services (8000)

akta.pro primary industry

Clinical Operations & Monitoring FSP (CRA/CTM/Start-up) (HLAGAOAA)

Keywords

• Clinical research services
• Biopharmaceutical solutions
• Contract research organization
• Pharmacovigilance services
• Clinical trial management

Headquarters

HQ city

Morrisville

HQ country

United States

HQ region

North America

Offices46 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Development Services: Full-service clinical development solutions spanning early phase (Phase I/IIa) through Phase II-IV clinical trials, including bioanalytical services, regulatory affairs, drug safety and pharmacovigilance, decentralized solutions, site and patient access, and patient recruitment and retention services.
2. Commercial Delivery: Full-service commercialization solutions including deployment solutions (field sales teams, engagement centers, medical science liaisons), communications (healthcare advertising, medical communications, PR), patient support services, and market access services.
3. Functional Service Provider (FSP 360): Customized outsourcing approach where sponsors retain oversight and strategic control while Syneos provides specialized staff in defined areas such as biostatistics, data management, clinical monitoring, medical writing, safety or regulatory support.
4. Medical Affairs: Strategic insight, scientific expertise, and organizational excellence via full suite of offerings supporting evidence-based strategies across the product lifecycle.
5. Real World Evidence and Late Phase Research: Observational and interventional late phase studies, RWD and evidence generation, health economics and outcomes research (HEOR), and pregnancy exposure research.
6. Consulting: Holistic management consulting, strategic planning and organizational transformation services including commercial advisory, scientific and medical affairs advisory, R&D advisory, and risk and program management advisory.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels9 records

Core offering

Syneos Health is a fully integrated end-to-end biopharmaceutical solutions organization providing clinical development services (Phase I-IV clinical trials, bioanalytical services, regulatory affairs, drug safety and pharmacovigilance, decentralized trials, site and patient access) and commercialization services (field sales deployment, medical science liaisons, engagement centers, communications, patient support, market access, and consulting). Revenue is generated primarily through professional services fees and managed services engagements under full-service or Functional Service Provider (FSP 360) models for biotech and pharmaceutical sponsors.

Product overview

Syneos Health is a fully integrated biopharmaceutical solutions organization offering both a unified platform and specialized modular solutions across the clinical-to-commercial continuum. The core portfolio includes Clinical Development (Phase I-IV, FSP 360, Real World Evidence, Decentralized Trials), Commercial Delivery (Deployment Solutions, Communications, Full-Service Commercialization), Medical Affairs, and Consulting services. Key technology products include Kinetic (commercial intelligence), Synopsis (clinical oversight), PatientGO (patient engagement), AI MSL Solutions, MODAL (learning), and PV Hub/PVCI (pharmacovigilance). The company has approximately 70% biotech customer portfolio and supports development/commercialization of 93% of FDA-approved novel drugs over the past five years.

Differentiator

Problem solved

Functional benefit

Brands

• PatientGO: Technology-enabled patient concierge application designed to expand trial access, accelerate recruitment, and improve retention in clinical trials.
• Synopsis
• FSP 360
• SyncUp Community
• Trusted Process

Products and services

• Clinical Development Services Full-service clinical development solutions spanning early phase (Phase I/IIa) through Phase II-IV clinical trials, including bioanalytical services, regulatory affairs, drug safety and pharmacovigilance, decentralized solutions, site and patient access, and patient recruitment and retention services for biotech and pharmaceutical sponsors.
• Commercial Delivery / Full-Service Commercialization Full-service commercialization solutions including deployment solutions (field sales teams, engagement centers, medical science liaisons), communications (healthcare advertising, medical communications, PR), patient support services, market access services, and learning solutions for pharmaceutical sponsors.
• Functional Service Provider (FSP 360) Customized outsourcing approach where sponsors retain oversight and strategic control while Syneos provides specialized staff in defined areas such as biostatistics, data management, clinical monitoring, medical writing, safety or regulatory support, embedding cross-functional teams within sponsor organizations.
• Medical Affairs Strategic insight, scientific expertise, and organizational excellence via full suite of offerings supporting evidence-based strategies across the product lifecycle for biotech and pharma clients.
• Real World Evidence and Late Phase Research Observational and interventional late phase studies, real-world data and evidence generation, health economics and outcomes research (HEOR), and pregnancy exposure research services for biopharmaceutical sponsors.
• Biopharmaceutical Consulting Holistic management consulting, strategic planning and organizational transformation services including commercial advisory, scientific and medical affairs advisory, R&D advisory, and risk and program management advisory for biopharmaceutical clients.
• Bioanalytical Services Bioanalytical services supporting large and small molecule drug development, including complex method development, validation and sample analysis via dedicated bioanalysis laboratories (Princeton, Quebec City) with 30+ years of experience and 1,200+ validated assays.
• Early Phase Clinical Research Early phase (Phase I/IIa) clinical research delivered through dedicated Clinical Research Units in Miami, FL and Quebec City, with 800+ scientific and medical experts and 30+ years of early phase experience supporting first-in-human studies.
• Drug Safety and Pharmacovigilance Pharmacovigilance and drug safety services spanning 6 continents with 1,700+ staff, delivering ICSR quality control, case intake, safety reporting, audits/inspections, and global regulatory compliance (99.5% compliance in 2024).
• Regulatory Affairs Regulatory affairs services with 300+ regulatory experts across the globe supporting biopharmaceutical sponsors with submissions, strategy, and health authority interactions across geographies.
• Decentralized and Hybrid Clinical Trials Decentralized and hybrid clinical trial solutions enabling home-based and remote trial delivery, supported by Illingworth Research Group for home health clinical research services.
• Patient Recruitment and Retention Patient recruitment and retention services including the StudyKIK platform, which pre-screened 21,400+ patients for clinical trial enrollment in 2024 and supports faster recruitment, decentralized outreach, and patient advocacy partnerships (50+).
• Site Engagement and Feasibility Automation (StudyEngage) Site engagement and feasibility automation platform streamlining site selection, activation, and support processes for clinical trials, including the StudyEngage investigator portal.
• Healthcare Advertising and Communications Syneos Health Communications offering healthcare advertising, medical communications, payer marketing, healthcare public relations, healthcare naming and brand identity, and human behavioral insights for pharmaceutical clients.
• Patient Support Services and Market Access Patient support services and market access solutions including field reimbursement management, patient engagement, value and access strategy, and specialty medication access delivered in partnership with CareMetx.
• Field Sales Teams and Deployment Solutions Deployment of field sales teams, medical science liaisons (MSLs), nurses, sales operations support, and recruiting and direct hire solutions for pharmaceutical field force needs.
• Engagement Center Deployment solution providing centralized engagement capabilities for pharmaceutical field teams, patient support services, and medical information call center operations.
• Veeva Vault CDMS Implementation Services Veeva-preferred services partner providing advisory, build, and operate support for Veeva Vault CDMS implementation, with case studies demonstrating up to 75% reduction in end-to-end data management cycle times.

Quantifiable outcome

• 93% of novel drugs approved by FDA in last 5 years developed or commercialized by Syneos Health
• +10 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability11 records

Feature8 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• KAI ConversationscoreTechnology or Integration · 14 May 2026Strategic AI partnership to embed KAI's conversation intelligence platform into Syneos Health's commercial solutions for the U.S. biopharma market. The collaboration aims to help pharmaceutical companies convert field team conversations with healthcare professionals into actionable coaching and brand intelligence. KAI's platform is currently used by 10 of the top 20 global pharmaceutical companies across 15 therapeutic areas and multiple continents.
• SageforcecoreTechnology or Integration · 14 May 2026Strategic AI partnership with Sageforce to enhance commercial intelligence capabilities through AI-powered field team engagement and optimization solutions for biopharma companies.
• causaLenscoreTechnology or Integration · 14 May 2026Strategic AI partnership with causaLens to integrate causal AI agents for commercial decision-making, enhancing Syneos Health's commercial intelligence ecosystem with causal AI-driven data science operations.
• BestudyminorStrategic or Co-development Partner · 19 March 2026Acquisition of Chinese CRO Bestudy to strengthen Syneos Health's position in China's growing biopharma market. The acquisition allows both companies to support global and local innovators in clinical development.
• MicrosoftcoreTechnology or Integration · 10 March 2026Syneos Health uses Microsoft Azure and Azure OpenAI Service for clinical trial operations. The company was featured as a case study demonstrating approximately 10% reduction in time for clinical trial site activation with Azure OpenAI Service. Part of broader healthcare AI transformation initiatives with Microsoft.
• CareMetxcoreStrategic or Co-development Partner · 22 October 2025Strategic partnership to deliver a next-generation access model for specialty medications, combining CareMetx's proprietary technology with Syneos Health's patient access and support solutions. The collaboration equips Syneos Health's Field Reimbursement Management and Patient Engagement teams with CareMetx's data, insights, and Access Partner Network to proactively address access challenges, streamline activation processes, and reduce integration burden for biopharma manufacturers.
• Microsoft Azure OpenAIcoreTechnology or Integration · 18 March 2025Syneos Health leverages Azure OpenAI Service to reduce time for clinical trial site activation by approximately 10%, demonstrating AI-powered operational efficiency improvements in clinical development.
• Boco Digital MediaminorStrategic or Co-development Partner · 18 August 2022Acquisition of Boco Digital Media, LLC, a digital media entity, as part of Syneos Health's strategic growth focus on biopharmaceutical solutions across clinical development and commercialization.
• RxDataScienceminorStrategic or Co-development Partner · 6 October 2021Acquisition of RxDataScience, a healthcare-focused data analytics and AI company, to enhance biopharma solutions. The deal aims to improve data transformation, insights, and analytics capabilities to accelerate product development and market performance.
• VeevacoreTechnology or IntegrationVeeva-preferred services partner providing advisory, implementation and business operations support for Veeva Vault CDMS. Case studies demonstrate up to 75% reduction in end-to-end data management cycle times when implemented correctly. Services span from assessing proof of concept to navigating early adoption and ramping up stack capabilities.
• Catalyst Site Network PartnerscoreChannel Partner/ Reseller/ DistributorCatalyst Site Network Partnership Program includes strategic partnerships with high-performing clinical trial sites globally. Recent additions include: Singapore General Hospital, GoBroad Healthcare Group (China), ACTIVATO (Japan), Kyushu University Hospital (Japan), Pacific Clinical Research Network (New Zealand), Siriraj Hospital (Thailand), University of the Sunshine Coast (Australia), Taipei Medical University Hospital (Taiwan), and P3 Research Ltd Network (New Zealand). Sites support faster clinical trial site activation and efficient delivery on studies.
• Syqe MedicalminorOthersSyneos Health subsidiary in Australia partnered with Syqe Medical for clinical trial services. Syqe Medical serves as international sponsor of clinical trial investigating medicinal cannabis for diabetic peripheral neuropathy, with Syneos handling recruitment site operations in Australia.

Scale indicators37 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Medpace Holdings: Mid-sized full-service CRO focused on Phase II–IV clinical trials for small and mid-sized biopharma; direct competitor in the biotech-heavy segment of Syneos's portfolio with a reputation for operating efficiency.
• ICON plc: Second-largest global CRO after acquiring PRA Health Sciences; competes head-to-head in Phase II–IV full-service clinical trials, FSP, bioanalytical services, and post-approval research for biopharma sponsors.
• Charles River Laboratories: Major CRO with strong discovery, preclinical, and clinical service offerings; competes with Syneos's early-phase and bioanalytical services, particularly for biotech sponsors running integrated discovery-through-Phase II programs.
• Parexel International: Private equity-owned (EQT/GS) global CRO with comparable full-service Phase II–IV, FSP, real-world evidence, and biopharma consulting offerings; one of Syneos's most direct functional competitors, particularly in oncology and rare disease.
• Fortrea (formerly LabCorp Drug Development / Covance): Spun off from LabCorp in 2023, Fortrea is a major clinical development and commercialization services CRO offering clinical trial management, central labs, and FSP — competing directly for biopharma Phase II–IV work.
• IQVIA: The largest global CRO and healthcare data/analytics company, offering full-service clinical development, FSP, real-world evidence, and commercial solutions across the biopharma value chain — directly overlapping with every Syneos service line.

Others

• Veeva Systems: Cloud software provider for life sciences (Vault CDMS, CTMS, eTMF); Syneos is a Veeva-preferred implementation partner for Veeva Vault CDMS, making Veeva both a strategic technology partner and a vendor whose broader clinical platform ambitions could overlap with Syneos's proprietary Synopsis and PV Hub offerings.
• Catalent: Recently acquired by Novo Holdings; a major CDMO and drug delivery services provider that competes with Syneos in adjacent biopharma services, including clinical supply and biologics development support across the same customer base.

Emerging players

• WuXi AppTec: China-based CRO/CDMO offering preclinical, clinical development, and bioanalytical services globally; competes with Syneos especially for China-based and APAC trials, and Syneos's 2026 acquisition of Bestudy reflects direct competitive positioning.

Broad incumbents

• Thermo Fisher Scientific (PPD): Owns PPD, a top-five global CRO, as part of its broader life sciences tools and services portfolio; offers clinical development, FSP, bioanalytical, and central lab services, and has deeper capital and R&D resources than Syneos.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/syneos-health
• Xx.com/syneoshealth

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries4 records

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A8 records

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Syneos Health